Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Mathé

Showing results (291-300 of 550) with videos related to

Pageof 55
Sort By:
Chemotherapy|January 1, 1986
Enhancement of NK-cell activity in normal and tumor-bearing mice after administration of aclacinomycinC E Andrade Mena, S Orbach-Arbouys, G Mathé
Nature|July 11, 1970
Powerful new inhibitor of murine leukaemia and sarcoma virusesJ C Chermann, M Raynaud, C Jasmin, et al.
Biomedicine / [Publiee Pour L'A.A.I.C.I.G.]|November 1, 1978
Non-H-2 antigens can induce high GVH mortality in adult recipients of normal cellsO Halle-Pannenko, L L Pritchard, R Motta, et al.
Israel Journal of Medical Sciences|April 1, 1976
Monitoring of nonspecific cell-mediated immunity in cancer patients. I. Frequent dissociation between the responses of skin tests to recall antigens and in vitro lymphocyte transformationM C Simmler, G Rameau, M J Chou, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1995
Lysosomal exocytosis induced by hyperthermia: a new model of cancer cell death. II. Effect on peritoneal macrophagesP Pontiggia, S Barni, G Mathé, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1996
Will killing the last HIV1 particle cure AIDS patients? II: Second Part. Decrease of viral load and of T-suppressor cells, and increase of the cytotoxic cells, without effect on CD4, after the use of 10 virostatics applied in 3 or 4 drug combinations of different sequences. The time for CD4 immunotherapy?G Mathé, U Colasanté, C Morette, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|July 12, 2002
Polyphenols: do they play a role in the prevention of human pathologies?H Tapiero, K D Tew, G Nguyen Ba, et al.
Israel Journal of Medical Sciences|April 1, 1976
Methanol extraction residue fraction of tubercle bacilli (MER) and other mycobacterial extracts as systemic immunity adjuvants in cancer immunotherapyG Mathé, I J Hiu, O Halle-Pannenko, et al.
Johns Hopkins Medical Journal. Supplement|January 1, 1974
The use of systemic immunity adjuvants in the prophylaxis or therapy of cancerG Mathé, O Halle-Pannenko, C Bourut, et al.
La Nouvelle Presse Medicale|July 2, 1977
[Does blastic crisis as revealed in chronic myeloid leukemia simulate either acute primary leukemia or acute primary leukemia with Philadelphia chromosome?]J L Misset, A M Venuat, L Nevarez, et al.
Pageof 55

Showing results (291-300 of 550) with videos related to

Sort By:
Pageof 55
Chemotherapy|January 1, 1986
Enhancement of NK-cell activity in normal and tumor-bearing mice after administration of aclacinomycinC E Andrade Mena, S Orbach-Arbouys, G Mathé
Nature|July 11, 1970
Powerful new inhibitor of murine leukaemia and sarcoma virusesJ C Chermann, M Raynaud, C Jasmin, et al.
Biomedicine / [Publiee Pour L'A.A.I.C.I.G.]|November 1, 1978
Non-H-2 antigens can induce high GVH mortality in adult recipients of normal cellsO Halle-Pannenko, L L Pritchard, R Motta, et al.
Israel Journal of Medical Sciences|April 1, 1976
Monitoring of nonspecific cell-mediated immunity in cancer patients. I. Frequent dissociation between the responses of skin tests to recall antigens and in vitro lymphocyte transformationM C Simmler, G Rameau, M J Chou, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1995
Lysosomal exocytosis induced by hyperthermia: a new model of cancer cell death. II. Effect on peritoneal macrophagesP Pontiggia, S Barni, G Mathé, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1996
Will killing the last HIV1 particle cure AIDS patients? II: Second Part. Decrease of viral load and of T-suppressor cells, and increase of the cytotoxic cells, without effect on CD4, after the use of 10 virostatics applied in 3 or 4 drug combinations of different sequences. The time for CD4 immunotherapy?G Mathé, U Colasanté, C Morette, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|July 12, 2002
Polyphenols: do they play a role in the prevention of human pathologies?H Tapiero, K D Tew, G Nguyen Ba, et al.
Israel Journal of Medical Sciences|April 1, 1976
Methanol extraction residue fraction of tubercle bacilli (MER) and other mycobacterial extracts as systemic immunity adjuvants in cancer immunotherapyG Mathé, I J Hiu, O Halle-Pannenko, et al.
Johns Hopkins Medical Journal. Supplement|January 1, 1974
The use of systemic immunity adjuvants in the prophylaxis or therapy of cancerG Mathé, O Halle-Pannenko, C Bourut, et al.
La Nouvelle Presse Medicale|July 2, 1977
[Does blastic crisis as revealed in chronic myeloid leukemia simulate either acute primary leukemia or acute primary leukemia with Philadelphia chromosome?]J L Misset, A M Venuat, L Nevarez, et al.
Pageof 55